aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.54

aTyr Pharma, Inc. (NASDAQ:LIFE) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.54 and traded as high as $1.70. aTyr Pharma shares last traded at $1.61, with a volume of 359,600 shares trading hands.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Royal Bank of Canada reduced their price objective on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, March 15th. HC Wainwright reissued a “buy” rating and set a $35.00 price objective on shares of aTyr Pharma in a research report on Friday, March 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $23.67.

aTyr Pharma Stock Down 5.3 %

The business has a 50-day simple moving average of $1.85 and a two-hundred day simple moving average of $1.54. The company has a market cap of $109.38 million, a price-to-earnings ratio of -1.68 and a beta of 1.25. The company has a quick ratio of 6.27, a current ratio of 6.27 and a debt-to-equity ratio of 0.02.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings results on Thursday, March 14th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). As a group, equities analysts forecast that aTyr Pharma, Inc. will post -0.97 earnings per share for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

A number of institutional investors have recently made changes to their positions in the business. FMR LLC increased its stake in shares of aTyr Pharma by 5.1% in the third quarter. FMR LLC now owns 8,556,925 shares of the biotechnology company’s stock worth $13,520,000 after purchasing an additional 413,162 shares during the period. Alyeska Investment Group L.P. increased its stake in aTyr Pharma by 79.4% during the first quarter. Alyeska Investment Group L.P. now owns 2,473,154 shares of the biotechnology company’s stock valued at $5,194,000 after acquiring an additional 1,094,407 shares during the period. Vanguard Group Inc. increased its stake in aTyr Pharma by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 2,368,454 shares of the biotechnology company’s stock valued at $3,340,000 after acquiring an additional 84,848 shares during the period. Samsara BioCapital LLC bought a new position in aTyr Pharma during the first quarter valued at about $3,675,000. Finally, BlackRock Inc. increased its stake in aTyr Pharma by 316.2% during the second quarter. BlackRock Inc. now owns 1,370,159 shares of the biotechnology company’s stock valued at $2,960,000 after acquiring an additional 1,040,982 shares during the period. 61.72% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.